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Objective: To compare the efficacy of “Oral ascorbic acid in combination with erythropoietin” with “standard 
dose of erythropoietin alone” in renal anemia in terms of mean hemoglobin rise. 
Materials and Methods: A total of 70 CKD patients with anemia, 18 to 70 years of age of both genders were 
included. Patients with laboratory-proven iron deficiency anemia, obvious blood loss, pernicious anemia, 
hyperparathyroidism, and contraindications for erythropoietin or ascorbic acid were excluded. It is important to 
mention here that dialysis patients were also excluded from the study. The patients were randomly selected and 
placed in two groups. Group A (erythropoietin alone) & Group B (erythropoietin plus oral ascorbic acid), by using 
the lottery method. Outcome variable like hemoglobin was measured at 2, 4 and 6 months. 
Results: Mean age was 48.90 ± 13.53 years. The male to female ratio was 1.6:1 with 43 (61.43%) males and 27 
(38.57%) females. Mean pre-therapy hemoglobin was 9.40 ± 1.03 g/dl in Group A while it was 9.42 ± 0.98 g/dl in 
Group B and mean post-therapy hemoglobin in Group A was 9.34 ± 1.06 g/dl while in Group B, it was 10.37 ± 
1.16 g/dl with a P-value of 0.0002 which is statistically significant. 
Conclusion: The study concluded that standard dose erythropoietin plus Oral ascorbic acid in CKD anemia is 
more effective as compared to erythropoietin alone. 
Keywords: Chronic kidney disease, Erythropoietin, Ascorbic acid, Anemia. 





CKD (Chronic kidney disease) has become a major 
health issue worldwide. For all the practical purposes, 
CKD is defined as either kidney damage or GFR 
(Glomerular filtration rate) of less than 90 
ml/min/1.73m2 for at least 3 months. Hypertension 
and diabetes are the leading cause of CKD ultimately 
progressing to ESRD (End Stage Renal disease) 
requiring renal replacement therapy (RRT). As CKD 
progresses, patients encounter many complications 
like anemia, bone mineral disease (BMD), reduced 
quality of life, increasing health expenditures, and 
premature deaths. In a population-based study 
conducted in South Asia to see the prevalence of CKD, 
unfortunately, Pakistan has the highest CKD 
prevalence when compared with India, Nepal, 
Bangladesh, and Sri Lanka.1 In the survey conducted 
in Karachi in 2011, 25.3% of the participants were 
found to have some degree of reduced GFR  with 
5% having GFR <60 ml/min.2  
 Renal anemia (defined as hemoglobin of less than 
10mg/dL) is a common finding in patients with 
chronic kidney disease. It is frequently normocytic and 
normochromic and typically a diagnosis of exclusion. 
Although renal anemia has multifactorial etiology, the 
main culprit is erythropoietin (EPO) deficiency. 
Erythropoietin is a hormone that is produced 
endogenously by the kidneys and helps in the 
maturation of RBCs. Other mechanisms which 
contribute to the development of anemia include bone 
marrow suppression by uremia, persistent state of 
inflammation, decreased iron absorption, increased 
levels of hepcidin, and vitamin deficiencies.3 Stauffer 
ME et al demonstrated in his study that prevalence of 
anemia is increased as CKD progresses; at stage 1 it 
was 8.4 % and increased to 53.4% at stage 5.4 
Anemia in CKD and hemodialysis patients is 
associated with increased mortality and 
hospitalization rates. However, the use of recombinant 
human erythropoietin (rhEpo) has altogether changed 
the management of anemia in the past three decades. 
It has been observed that some patients respond 
poorly to erythropoietin therapy. Iron deficiency is the 
major reason behind erythropoietin hypo-
responsiveness although the contributory role of 
chronic inflammation, oxidative stress, and some 
erythropoiesis inhibitory factors has also been 
evaluated.5  
Ascorbic acid (AA) is a vital nutrient and its role in the 
management of anemia has been evaluated in the 
hemodialysis population in many different studies. 
Ascorbic acid increases the delivery of iron from the 
ferritin and reticuloendothelial system and therefore 
elevates iron use during heme synthesis. Tanjim 
Sultana et al studied the role of ascorbic acid and 
found it helpful in decreasing EPO dose requirement 
in hemodialysis patients.6 
Since higher mortality and morbidity are associated 
with anemia in CKD patients, careful correction of 
anemia carries major benefits in terms of improvement 
in quality of life, and better tolerance for physical 
effort. EPO is not only expensive, the higher than 
standard dose of EPO is associated with poor 
outcomes. So, proving the beneficial effects of ascorbic 
acid in the treatment of renal anemia can help us 
achieve better outcomes at a lower EPO dose.  
 
Materials and Methods 
 
This RCT was done from July 2019 to August 2020 in 
the Nephrology department of a tertiary care hospital. 
70 patients of both genders with CKD (excluding 
dialysis patients) and anemia (Hb<10 g/dl) and age 
between 18-70 years were included. Patients with iron 
deficiency anemia, pernicious anemia, blood loss, 
hyperparathyroidism, and contraindications for 
erythropoietin or ascorbic acid were excluded.  
After taking informed consent, the patients were 
selected randomly and placed in two groups i.e. 
Group A (erythropoietin alone) and Group B 
(erythropoietin plus oral ascorbic acid), using the 
lottery method. Group A patients were treated with 
erythropoietin alone: 50 IU/kg twice weekly) and  
Group B patients received erythropoietin 50 IU/kg 
two times a week along with daily 500 mg oral 
ascorbic acid. All patients were followed by taking 
contact numbers and home addresses over a period of 
6 months and were reviewed by a consultant 
nephrologist. All parameters recorded at the initial 
assessment were checked and the dose of 
erythropoietin was adjusted accordingly. Outcome 
variable like hemoglobin was measured at 2, 4 and 6 
months and reports were verified by consultant 
hematologist.  
We decided on primary efficacy and safety end-points. 
The total number of patients achieving equal or more 
than hemoglobin levels of 12 mg/dL in the last month 
of treatment were labelled as the primary efficacy end-
point. Safety end-points were severe anemia (Hb less 
than 6), lymphopenia with severe infection, and 
opportunistic infections. Patients who needed blood 
transfusion for any reason were excluded. All selected 
patients were kept devoid of iron therapy throughout 
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the 6 months of study and patients who had T-
Saturation less than 25 were also excluded. Patients 
were monitored for side effects of ascorbic acid like 
nausea, vomiting, heartburn, and oxalosis on regular 
basis. 
All data were recorded and analyzed in SPSS v 20.0. 
The percentages and frequencies were calculated for 
the categorical variables. For continuous variables 
mean and Standard deviation were calculated. The 
student’s t-test was used for assessment of the 
significance of the difference between two groups for 
continuous variables (mean Hb). A p-value of < 0.05 




Of the total 266 medical students enrolled in this 
research, most (53.75%) of our study participants were 
final-year MBBS students as depicted in Figure 1. 
The mean age of the patients in group A was 48.49 ± 
13.77 years and in group B was 49.31 ± 13.48 years. 
The majority of patients 25 (35.71%) were of 46 to 60 
years of age. Out of the total 70 patients, 43(61.43%) 
patients were males and 27(38.57%) patients were 
females with a ratio of 1.6:1.  
Figure 1 shows the mean pre-therapy hemoglobin in 
both groups with no significant difference among 
them (p-value = 0.901). The mean duration of disease 
was 4.64 ± 2.41 months. Majority of patients presented 
with stage 5 CKD i.e. 23 (32.86%) in both groups as 
shown in Figure 2. Mean post-therapy hemoglobin in 
Group A (erythropoietin alone) was 9.34 ± 1.06 g/dl 
while in Group B (erythropoietin plus ascorbic acid) 








Figure 1: Mean pre-therapy Hemoglobin in both 
groups
 
Figure 2: Distribution of patients according to the 
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P-value = 0.0002 which is statistically significant. 
Figure 3: Comparison of Post-therapy mean 




The CKD burden worldwide is increasing enormously 
and a 19.6% increase in prevalence has been reported 
from 2005 to 2015 based on data collected from 
different studies.7 Aggregated results from different 
studies conducted in the USA and Europe showed a 
significant rise in CKD prevalence, however, 
sometimes there is marked disparity among the 
countries like 3.3% in Norway and 17.3% in north 
Germany.7 
The introduction of erythropoietin in clinical practice 
about 30 years back dramatically changed the 
management of anemia which is associated with CKD. 
Renal anemia is found in more than half of the patients 
diagnosed with stages 4 and 5 of CKD.8 Before the 
EPO therapy, patients dependent on dialysis were 
profoundly anemic usually having hemoglobin 
between 6 g/dl to 7g/dl; blood transfusion and iron 
therapy being only available treatments. The use of 
erythropoietin to maintain hemoglobin levels between 
10 and 12.0 g/dl is recommended9, however, 
erythropoietin use is not without risks. It should be 
avoided in patients with active malignancy and may 
be used with caution in patients with a previous 
history of stroke and neoplasia.9 
The use of ascorbic acid in renal anemia has been a 
matter of debate in the last decade. The study which 
was conducted by Salih Karahan et al found that 
baseline ascorbic acid levels were lower in kidney 
patients and administration of ascorbic acid 
profoundly decreased central blood pressure and 
increased antioxidant potential of the patients.10 
In a study conducted at Mazandaran University of 
Medical Sciences, Sari, Iran, the author showed 
significant mean hemoglobin rise in a group of 
patients who received intravenous ascorbic acid with 
each hemodialysis session along with erythropoietin 
(before 8.5 ± 1.2; after 9.6 ± 1.4) whereas mean 
hemoglobin in patients who received only 
erythropoietin did not show such improvement 
(before 8.5 ± 1.1; after 8.4 ± 1.3).11 
In our study, we wanted to see the effect of ascorbic 
acid on anemia of kidney patients who were not on 
dialysis yet. The majority of the patients 25 (35.71%) in 
our study were between 46 to 60 years of age. The 
patients were treated for iron deficiency anemia (if 
any) before inclusion into the study. No patient was 
receiving any iron supplementation throughout the 
study to decrease the bias. Mean pre-therapy 
hemoglobin in Group A (erythropoietin alone) was 
9.40 ± 1.03 g/dl while in Group B (erythropoietin plus 
ascorbic acid) was 9.42 ± 0.98 g/dl and mean post-
therapy hemoglobin in Group A (erythropoietin alone) 
was 9.34 ± 1.06 g/dl while in Group B (erythropoietin 
plus ascorbic acid) was 10.37 ± 1.16 g/dl with a p-
value of 0.0002 which was statistically significant. 
Patients on ascorbic acid responded comparatively 
better to EPO probably because of its antioxidant 
properties and ability to counterbalance radical 
species. Ascorbic acid may also play an important role 
in iron metabolism and its application in red blood cell 
formation so the total dose of EPO consumed to 
achieve the same hemoglobin may be reduced as well. 
Interestingly oral ascorbic acid was tolerated well by 
the patients and no side effects were noted. 
Similar findings were elaborated by Jalalzadeh M et al 
in his study where he found that after 3 months of 
treatment, Hb levels increased from 10.11g/dl to 12.19 
g/dl (P < 0.001; 95% confidence interval [CI] 2.7-1.4) in 
patients who were treated with erythropoietin plus 
ascorbic acid for correction of their anemia.12 
Sharkawy M. et al likewise showed a significant 
increase in mean values of hemoglobin levels in the 
erythropoietin plus ascorbic acid group from 7.85 ± 
0.96 to 9.26 ± 1.17 (p<0.001) in comparison to the 
erythropoietin group.13  
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In another recent study which was conducted in a 
small group of hemodialysis patients, there was a 33% 
decrease in EPO requirement in patients who were 
treated with 250 mg of ascorbic acid daily for 3 months 
along with erythropoietin. Hb levels increase 
significantly from 10.1 ± 0.6 mg/dl to 10.7 ± 0.6 mg/dL 
(P = 0.03) and there were no particular side effects of 




This study concluded that standard dose 
erythropoietin plus oral ascorbic acid is more effective 
for anemia correction in chronic kidney disease 
patients and results are encouraging when compared 
with erythropoietin alone. Ascorbic acid is cheap and 
available freely in Pakistan So, we recommend that 
ascorbic acid along with erythropoietin can be used as 
first-line therapy in order to achieve better outcomes at 
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